TY  - JOUR
AU  - Rasouli, Hassan
AU  - Ramalho, Teodorico C.
AU  - Popović-Djordjević, Jelena B.
AU  - Devkota, Hari Prasad
PY  - 2023
UR  - http://aspace.agrif.bg.ac.rs/handle/123456789/6335
T2  - Frontiers in Pharmacology
T2  - Frontiers in Pharmacology
T1  - Editorial: New opportunities in drug design for the management and treatment of type 2 diabetes
VL  - 14
DO  - 10.3389/fphar.2023.1187057
ER  - 

@article{
author = "Rasouli, Hassan and Ramalho, Teodorico C. and Popović-Djordjević, Jelena B. and Devkota, Hari Prasad",
year = "2023",
journal = "Frontiers in Pharmacology, Frontiers in Pharmacology",
title = "Editorial: New opportunities in drug design for the management and treatment of type 2 diabetes",
volume = "14",
doi = "10.3389/fphar.2023.1187057"
}

Rasouli, H., Ramalho, T. C., Popović-Djordjević, J. B.,& Devkota, H. P.. (2023). Editorial: New opportunities in drug design for the management and treatment of type 2 diabetes. in Frontiers in Pharmacology, 14.
https://doi.org/10.3389/fphar.2023.1187057

Rasouli H, Ramalho TC, Popović-Djordjević JB, Devkota HP. Editorial: New opportunities in drug design for the management and treatment of type 2 diabetes. in Frontiers in Pharmacology. 2023;14.
doi:10.3389/fphar.2023.1187057 .

Rasouli, Hassan, Ramalho, Teodorico C., Popović-Djordjević, Jelena B., Devkota, Hari Prasad, "Editorial: New opportunities in drug design for the management and treatment of type 2 diabetes" in Frontiers in Pharmacology, 14 (2023),
https://doi.org/10.3389/fphar.2023.1187057 . .

TY  - JOUR
AU  - Rasouli, Hassan
AU  - Ramalho, Teodorico C.
AU  - Popović-Djordjević, Jelena B.
AU  - Devkota, Hari Prasad
PY  - 2023
UR  - https://www.frontiersin.org/articles/10.3389/fphar.2023.1187057
UR  - http://aspace.agrif.bg.ac.rs/handle/123456789/6374
T2  - Frontiers in Pharmacology
T2  - Frontiers in Pharmacology
T1  - Editorial: New opportunities in drug design for the management and treatment of type 2 diabetes
VL  - 14
DO  - 10.3389/fphar.2023.1187057/full
ER  - 

@article{
author = "Rasouli, Hassan and Ramalho, Teodorico C. and Popović-Djordjević, Jelena B. and Devkota, Hari Prasad",
year = "2023",
journal = "Frontiers in Pharmacology, Frontiers in Pharmacology",
title = "Editorial: New opportunities in drug design for the management and treatment of type 2 diabetes",
volume = "14",
doi = "10.3389/fphar.2023.1187057/full"
}

Rasouli, H., Ramalho, T. C., Popović-Djordjević, J. B.,& Devkota, H. P.. (2023). Editorial: New opportunities in drug design for the management and treatment of type 2 diabetes. in Frontiers in Pharmacology, 14.
https://doi.org/10.3389/fphar.2023.1187057/full

Rasouli H, Ramalho TC, Popović-Djordjević JB, Devkota HP. Editorial: New opportunities in drug design for the management and treatment of type 2 diabetes. in Frontiers in Pharmacology. 2023;14.
doi:10.3389/fphar.2023.1187057/full .

Rasouli, Hassan, Ramalho, Teodorico C., Popović-Djordjević, Jelena B., Devkota, Hari Prasad, "Editorial: New opportunities in drug design for the management and treatment of type 2 diabetes" in Frontiers in Pharmacology, 14 (2023),
https://doi.org/10.3389/fphar.2023.1187057/full . .

TY  - JOUR
AU  - Rasouli, Hassan
AU  - Yarani, Reza
AU  - Pociot, Flemming
AU  - Popović-Djordjević, Jelena
PY  - 2020
UR  - http://aspace.agrif.bg.ac.rs/handle/123456789/5402
AB  - Diabetes mellitus (DM) is a chronic metabolic disease which causes millions of death all over the world each year, and its incidence is on increase. The most prevalent form, type 2 DM, is characterized by insulin resistance and beta-cell dysfunction, whereas type 1 DM is due to insulin deficiency as a result of beta-cell destruction. Various classes of synthetic drugs have been developed to regulate glucose homeostasis and combat the development of late-diabetic complications. However, several of these chemical agents are either sub-optimal in their effect and/ or may have side effects. Biologically, alkaloids unveiled a wide range of therapeutic effects including antidiabetic properties. The chemical backbones of these compounds have the potential to interact with a wide range of proteins involved in glucose homeostasis, and thus they have received increasing attention as reliable candidates for drug development. This review sets out to investigate the anti-diabetic potential of plant alkaloids (PAs), and therefore, scientific databases were comprehensively screened to highlight the biological activity of 78 PAs with a considerable anti-diabetic profile. There are not enough clinical data available for these phytochemicals to follow their fingerprint in human, but current studies generally recommending PAs as potent alpha-glucosidase inhibitors. Except for some classes of monoterpene alkaloids, other compounds showed similar features as well as the presently available anti-diabetic drugs such as amino sugars and other relevant drugs. Moreover, the evidence suggests that PAs have the potential to be used as alternative additives for the treatment of DM, however, further in vitro and in vivo studies are needed to validate these findings.
PB  - Academic Press Ltd- Elsevier Science Ltd, London
T2  - Pharmacological Research
T1  - Anti-diabetic potential of plant alkaloids: Revisiting current findings and future perspectives
VL  - 155
DO  - 10.1016/j.phrs.2020.104723
ER  - 

@article{
author = "Rasouli, Hassan and Yarani, Reza and Pociot, Flemming and Popović-Djordjević, Jelena",
year = "2020",
abstract = "Diabetes mellitus (DM) is a chronic metabolic disease which causes millions of death all over the world each year, and its incidence is on increase. The most prevalent form, type 2 DM, is characterized by insulin resistance and beta-cell dysfunction, whereas type 1 DM is due to insulin deficiency as a result of beta-cell destruction. Various classes of synthetic drugs have been developed to regulate glucose homeostasis and combat the development of late-diabetic complications. However, several of these chemical agents are either sub-optimal in their effect and/ or may have side effects. Biologically, alkaloids unveiled a wide range of therapeutic effects including antidiabetic properties. The chemical backbones of these compounds have the potential to interact with a wide range of proteins involved in glucose homeostasis, and thus they have received increasing attention as reliable candidates for drug development. This review sets out to investigate the anti-diabetic potential of plant alkaloids (PAs), and therefore, scientific databases were comprehensively screened to highlight the biological activity of 78 PAs with a considerable anti-diabetic profile. There are not enough clinical data available for these phytochemicals to follow their fingerprint in human, but current studies generally recommending PAs as potent alpha-glucosidase inhibitors. Except for some classes of monoterpene alkaloids, other compounds showed similar features as well as the presently available anti-diabetic drugs such as amino sugars and other relevant drugs. Moreover, the evidence suggests that PAs have the potential to be used as alternative additives for the treatment of DM, however, further in vitro and in vivo studies are needed to validate these findings.",
publisher = "Academic Press Ltd- Elsevier Science Ltd, London",
journal = "Pharmacological Research",
title = "Anti-diabetic potential of plant alkaloids: Revisiting current findings and future perspectives",
volume = "155",
doi = "10.1016/j.phrs.2020.104723"
}

Rasouli, H., Yarani, R., Pociot, F.,& Popović-Djordjević, J.. (2020). Anti-diabetic potential of plant alkaloids: Revisiting current findings and future perspectives. in Pharmacological Research
Academic Press Ltd- Elsevier Science Ltd, London., 155.
https://doi.org/10.1016/j.phrs.2020.104723

Rasouli H, Yarani R, Pociot F, Popović-Djordjević J. Anti-diabetic potential of plant alkaloids: Revisiting current findings and future perspectives. in Pharmacological Research. 2020;155.
doi:10.1016/j.phrs.2020.104723 .

Rasouli, Hassan, Yarani, Reza, Pociot, Flemming, Popović-Djordjević, Jelena, "Anti-diabetic potential of plant alkaloids: Revisiting current findings and future perspectives" in Pharmacological Research, 155 (2020),
https://doi.org/10.1016/j.phrs.2020.104723 . .